# EDGAR Filing Document

**Accession Number:** 0001287098
**File Stem:** 0001104659-26-036201
**Filing Date:** 2026-3
**Character Count:** 11658
**Document Hash:** f8f9618dea04b62d2fab6e048357bd8f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-036201.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0001104659-26-036201

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260323

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAXCYTE, INC.
- **CENTRAL INDEX KEY:** 0001287098
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 522210438
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40674
- **FILM NUMBER:** 26808234

**BUSINESS ADDRESS:**
- **STREET 1:** 9713 KEY WEST AVENUE,
- **STREET 2:** SUITE 400
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 301-517-5556

**MAIL ADDRESS:**
- **STREET 1:** 9713 KEY WEST AVENUE,
- **STREET 2:** SUITE 400
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAXCYTE INC
- **DATE OF NAME CHANGE:** 20040415

?xml version='1.0' encoding='ASCII'? MaxCyte, Inc._March 23, 2026

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 23, 2026**

**MaxCyte, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40674** | **52-2210438** |
| (State or other jurisdiction of <br>incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

**9713 Key West Avenue, Suite 400** 

**Rockville, Maryland 20850**

(Address of principal executive offices, including zip code)

**(301) 944-1700**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **TradingSymbol(s)** | **Name of each exchange** <br>**on which registered** |
| **Common Stock, $0.01 par value** | **MXCT** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

***Appointment of Parmeet Ahuja as Chief Financial Officer***

On March 23, 2026, the Board of Directors (the "***Board***") of MaxCyte, Inc. (the "***Company***") appointed Parmeet Ahuja as the Company's Chief Financial Officer, effective March 30, 2026. Mr. Ahuja will also serve as the Company's principal accounting officer. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025.

Prior to joining MaxCyte, Mr. Ahuja, 57, served as Vice President, Investor Relations of Agilent Technologies, Inc., a life sciences tools company, ("Agilent") from August 2021 to October 2025, and previously served as Vice President, Financial Planning and Analysis, Operations and Supply Chain at Agilent from July 2017 to July 2021. Mr. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization. Previously, he held several leadership roles at Agilent in operational finance, financial planning and analysis, enterprise audit and controls, and global financial operations. Mr. Ahuja holds an MBA from San Jose State University and a Bachelor of Commerce (Hons) from Delhi University.

There are no family relationships between Mr. Ahuja and any director or executive officer of the Company and no transaction involving Mr. Ahuja that would require disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Ahuja and any other persons pursuant to which he was selected to serve as the Company's principal financial officer.

Mr. Ahuja will receive an annual base salary of $450,000 and will be eligible to receive an annual cash performance bonus with an initial target bonus percentage equal to 50% of his base salary. In connection with his employment, as an inducement for Mr. Ahuja to join the Company, Mr. Ahuja will be granted a nonqualified stock option to purchase 375,000 shares of the Company's common stock and a restricted stock unit award with respect to 187,500 shares of the Company's common stock.

The Company expects to enter into the Company's form of severance agreement with Mr. Ahuja. Under the form of severance agreement, if Mr. Ahuja is terminated by the Company other than for "cause" (as defined in the severance agreement), or if he resigns for "good reason" (as defined in the severance agreement), and if such termination or resignation occurs within three months prior or during the twelve month period ending on the anniversary of a "change of control" (as defined in the severance agreement), then Mr. Ahuja would be eligible to receive (i) payment of his monthly base salary (calculated as his total base salary during the 12-month period prior to his date of termination divided by 12) for the 12 months following his departure (less applicable tax withholdings), (ii) 100% of his "target bonus" (as defined in the severance agreement) (less applicable tax withholdings) paid in monthly installments over 12 months, (iii) COBRA premium coverage for up to 12 months, and (iv) full acceleration of the vesting of the unvested shares subject to his outstanding equity awards. If Mr. Ahuja is terminated by the Company other than for "cause," or if he resigns for "good reason," and if such termination or resignation occurs more than three months prior to a "change in control," then Mr. Ahuja would be eligible to receive (i) payment of his monthly base salary (calculated as his total base salary during the 12-month period prior to his date of termination divided by 12) for the nine months following his departure (less any amounts paid to Mr. Ahuja during such nine-month period under the Company's short-term or long-term disability plans, and less applicable tax withholdings) and (ii) COBRA premium coverage for up to nine months.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits** 

---

| | |
|:---|:---|
| **Arch** <br>|  |
| **Exhibit** <br>**Number** | **Exhibit Description** |
| 99.1 | [Press Release, dated March 23, 2026](mxct-20260323xex99d1.htm) |
| 104 | Cover Page Interactive Data (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MaxCyte, Inc.** | **MaxCyte, Inc.** |
| Dated: March 27, 2026 | By: | /s/ Maher Masoud |
|  |  | Maher Masoud |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer**

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) – MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025.

"Parmeet is an exceptionally talented finance leader whose experience and expertise position him well to strengthen MaxCyte's financial operations," said Maher Masoud, Chief Executive Officer. "His deep background in financial operations, strategic FP&A, and investor relations, developed over more than two decades at Agilent, makes him well suited to support our next phase of growth. We are confident in Parmeet's ability to partner across our organization and further elevate finance's strategic role."

Mr. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization, most recently serving as Vice President, Investor Relations at Agilent Technologies, where he worked closely with senior leadership to help shape and communicate the company's narrative to analysts and investors. Previously, he held several leadership roles at Agilent in operational finance, financial planning and analysis, enterprise audit and controls, and global financial operations. Mr. Ahuja holds an MBA in Finance from San Jose State University and a Bachelor of Commerce in Accounting from Delhi University.

"I am honored to join MaxCyte at a pivotal moment in the company's trajectory," said Parmeet Ahuja. "MaxCyte's electroporation platform is transformative for the Cell and Gene Therapy industry, and I am excited to contribute to the company's continued success. I look forward to working with Maher and the entire MaxCyte team to strengthen our financial foundation, support disciplined execution, and advance the company's strategic priorities."

**About MaxCyte**

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

**MaxCyte Contacts:**

**Investor Relations**

Gilmartin Group

David Deuchler, CFA

ir@maxcyte.com

**Media Contact**

Oak Street Communications

Kristen White

+1 415-608-6060

kristen@oakstreetcommunications.com

------